Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories
In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux’s career as a PharmD,
PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics’ potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory’s suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs’ efficacy and safety.
Disclaimer:
Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity.
00:00:06,190 --> 00:00:19,620
You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry.
00:00:20,079 --> 00:00:24,750
Precision medicine brings a ray of hope for those seeking customized health care.
00:00:25,350 --> 00:00:32,830
Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended.
00:00:33,540 --> 00:00:44,680
Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care.
00:00:45,169 --> 00:00:52,790
Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time.
00:00:52,799 --> 00:00:53,189
00:00:53,200 --> 00:00:53,950
00:00:54,159 --> 00:00:55,080
00:00:55,090 --> 00:00:56,389
00:00:56,409 --> 00:01:09,860
And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast.
00:01:09,870 --> 00:01:16,690
We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX.
00:01:16,769 --> 00:01:23,849
We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics.
00:01:23,860 --> 00:01:29,720
Industry leaders such as today's special guest and my name is Baas Sami,
00:01:29,730 --> 00:01:32,739
the co-host of PGX for Pharms podcast,
00:01:32,750 --> 00:01:33,860
00:01:33,870 --> 00:01:36,819
medical science liaison and a mentor to pharmacist.
00:01:36,889 --> 00:01:40,239
Connect with us on linkedin and let's get a conversation going.
00:01:40,269 --> 00:01:46,720
We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey.
00:01:48,510 --> 00:01:49,010
00:01:49,019 --> 00:01:50,819
So without any further ado,
00:01:50,839 --> 00:01:54,769
I'm extremely pleased to introduce to our audience.
00:01:54,919 --> 00:01:56,059
00:01:57,239 --> 00:02:01,129
the Chief Scientific Officer at Prometheus Laboratories,
00:02:01,139 --> 00:02:08,139
and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis,
00:02:08,149 --> 00:02:13,330
prognosis and monitoring of immune mediated inflammatory diseases.
00:02:13,970 --> 00:02:14,229
00:02:14,240 --> 00:02:14,649
00:02:14,660 --> 00:02:17,759
Doctor De for joining us on the podcast.
00:02:17,770 --> 00:02:18,589
00:02:18,600 --> 00:02:23,190
I'm excited to share your and Prometheus's story with our audience.
00:02:23,649 --> 00:02:25,630
00:02:25,639 --> 00:02:45,369
I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders.
00:02:46,119 --> 00:02:46,449
00:02:46,460 --> 00:03:04,220
one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test.
00:03:04,229 --> 00:03:08,020
Most of them or most of you are uh familiar with.
00:03:09,020 --> 00:03:09,429
00:03:09,440 --> 00:03:22,179
Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert.
00:03:23,619 --> 00:03:23,800
00:03:23,809 --> 00:03:24,250
00:03:24,259 --> 00:03:25,759
00:03:25,770 --> 00:03:26,850
00:03:26,860 --> 00:03:27,289
00:03:27,300 --> 00:03:30,820
I am a pharmacist uh with uh a family who is a,
00:03:30,830 --> 00:03:33,039
a doctorate in pharmacokinetics.
00:03:33,539 --> 00:03:44,520
Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents,
00:03:44,929 --> 00:03:49,160
uh primarily uh six Maturin as well as methotrexate.
00:03:49,169 --> 00:03:50,550
00:03:50,770 --> 00:03:52,960
uh I moved uh in industry for promet.
00:03:53,490 --> 00:04:01,429
So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease.
00:04:01,509 --> 00:04:12,550
Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites.
00:04:12,559 --> 00:04:13,029
00:04:13,050 --> 00:04:21,989
uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today.
00:04:23,660 --> 00:04:24,220
00:04:24,230 --> 00:04:27,359
So thank you for qualifying yourself as an expert.
00:04:27,369 --> 00:04:27,619
00:04:27,630 --> 00:04:32,839
let's jump right in and delve into your current PGX work.
00:04:32,850 --> 00:04:33,279
00:04:33,489 --> 00:04:36,540
if you'll tell us um a little about Prometheus,
00:04:36,549 --> 00:04:38,000
00:04:38,010 --> 00:04:40,350
what is Prometheus's mission?
00:04:40,359 --> 00:04:43,799
And how are you guys going about accomplishing your mission?
00:04:44,760 --> 00:04:44,980
00:04:44,989 --> 00:04:45,700
00:04:45,709 --> 00:04:47,459
00:04:47,470 --> 00:04:52,790
is a reference uh clinical laboratory based in Southern California in San Diego.
00:04:53,230 --> 00:04:56,809
Uh The company has been there for uh over 25 years.
00:04:56,820 --> 00:05:03,950
We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders,
00:05:04,059 --> 00:05:06,019
uh gastrointestinal disorder,
00:05:06,230 --> 00:05:08,619
uh and inflammatory bowel disease.
00:05:08,980 --> 00:05:10,299
00:05:10,309 --> 00:05:16,600
we have developed a portfolio of a differentiated solution to facilitate the diagnosis,
00:05:16,609 --> 00:05:17,470
00:05:17,480 --> 00:05:18,429
00:05:18,660 --> 00:05:21,910
as well as therapy selection with pharmacogenetics testing,
00:05:21,920 --> 00:05:24,730
which we are offering to our clinical laboratory.
00:05:24,829 --> 00:05:26,350
00:05:26,410 --> 00:05:27,299
00:05:27,309 --> 00:05:35,660
we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics.
00:05:36,470 --> 00:05:37,130
00:05:37,140 --> 00:05:37,329
00:05:37,339 --> 00:05:37,450
00:05:37,459 --> 00:05:38,049
00:05:38,059 --> 00:05:46,100
Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients?
00:05:46,109 --> 00:05:49,230
how they benefit medication therapy management.
00:05:49,239 --> 00:05:56,429
Stakeholders across the IB DS patients journey from diagnosis to treatment to disease,
00:05:56,440 --> 00:06:02,049
monitoring through remission and how they differ from other lab tests for IBD and his treatments.
00:06:02,709 --> 00:06:03,209
00:06:03,220 --> 00:06:03,369
00:06:03,380 --> 00:06:04,399
00:06:04,410 --> 00:06:10,100
our clinical laboratory offers some uh highly specialized test to facilitate the,
00:06:10,109 --> 00:06:16,779
the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease.
00:06:16,790 --> 00:06:22,359
So we are following uh testing solution with uh serological testing,
00:06:22,529 --> 00:06:23,799
00:06:23,809 --> 00:06:38,410
uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis.
00:06:39,339 --> 00:06:43,684
These are conditions that are uh uh somewhat difficult to treat.
00:06:43,704 --> 00:06:49,994
Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist.
00:06:50,015 --> 00:06:51,114
00:06:51,125 --> 00:07:03,434
to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder.
00:07:03,445 --> 00:07:05,635
When the diagnostic is established,
00:07:05,910 --> 00:07:31,839
uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know,
00:07:31,850 --> 00:07:36,559
establish de determining some genotyping with the fit transferal genotyping.
00:07:36,570 --> 00:07:37,279
00:07:37,290 --> 00:07:40,250
where we can uh indicate that the patient is,
00:07:40,260 --> 00:07:45,079
is likely uh to present with a side effect to those medication.
00:07:45,399 --> 00:07:46,170
00:07:46,179 --> 00:07:47,799
the the treatment is initiative,
00:07:47,809 --> 00:08:16,089
we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal.
00:08:16,980 --> 00:08:24,040
So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution.
00:08:24,049 --> 00:08:30,250
With our goal being to improve the uh the outcome uh of patients with uh with diabetes.
00:08:30,260 --> 00:08:34,520
And I think that the pharmacist has a very important role to play from that perspective.
00:08:35,179 --> 00:08:36,039
00:08:36,049 --> 00:08:40,239
could you elaborate for us more on the predictor test?
00:08:40,249 --> 00:08:42,758
Um especially since you designed that test,
00:08:42,768 --> 00:08:44,218
we'd really like to know,
00:08:44,489 --> 00:08:45,039
00:08:45,049 --> 00:08:49,638
what did that take and what role does it play in your suite of testing?
00:08:51,049 --> 00:08:51,270
00:08:51,280 --> 00:08:51,890
00:08:51,900 --> 00:08:52,510
00:08:52,520 --> 00:08:52,570
00:08:52,580 --> 00:08:52,989
00:08:53,000 --> 00:08:53,229
00:08:53,239 --> 00:08:59,960
the predictor test is uh uh is uh is utilized when the patient is receiving treatment.
00:09:00,280 --> 00:09:18,190
It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory.
00:09:18,200 --> 00:09:21,549
This is what the test does is to you connect the blood specimen,
00:09:22,229 --> 00:09:23,049
00:09:23,059 --> 00:09:24,750
00:09:25,039 --> 00:09:41,989
And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient.
00:09:42,169 --> 00:09:43,729
Typically a vast majority,
00:09:43,739 --> 00:09:46,159
about two third of a third to two third,
00:09:46,169 --> 00:09:54,669
a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication.
00:09:54,989 --> 00:09:57,960
Uh Not because they don't have the uh you know,
00:09:57,969 --> 00:09:59,289
typically because they have a,
00:09:59,299 --> 00:09:59,590
00:09:59,599 --> 00:10:05,599
pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know,
00:10:05,609 --> 00:10:09,440
unresponsive because uh not enough drug has been given.
00:10:09,450 --> 00:10:18,469
So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient.
00:10:18,750 --> 00:10:24,729
And from then uh re report the best dose uh to give in order to achieve the,
00:10:24,760 --> 00:10:31,570
the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient.
00:10:32,169 --> 00:10:33,059
00:10:33,070 --> 00:10:38,049
we have developed a test for the Infliximab as well as Adalimumab which is Humira,
00:10:38,909 --> 00:10:41,309
but these are antimony causes factor.
00:10:41,460 --> 00:10:49,549
And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of,
00:10:49,559 --> 00:10:51,969
of uh inflammatory bubble disease.
00:10:51,979 --> 00:10:52,669
00:10:52,679 --> 00:10:55,450
uh for MET is a suite of tests.
00:10:55,460 --> 00:11:00,940
Goes well beyond um the PGX testing that our audience is most familiar with,
00:11:01,299 --> 00:11:08,679
uh which typically only includes snips for cyp genes and some pharmacodynamic genes.
00:11:08,690 --> 00:11:31,424
This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know,
00:11:31,434 --> 00:11:36,054
it was developed by a larger laboratory for maybe smaller laboratories use.
00:11:36,729 --> 00:11:39,010
00:11:39,020 --> 00:11:53,729
having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests.
00:11:53,739 --> 00:11:54,119
00:11:54,130 --> 00:12:00,729
could you elaborate for our audience on the difficulties that are associated with immunology,
00:12:00,739 --> 00:12:05,830
research and developing tests uh for immunology versus say oncology?
00:12:06,330 --> 00:12:06,530
00:12:06,539 --> 00:12:07,049
00:12:07,059 --> 00:12:09,969
00:12:09,979 --> 00:12:11,590
00:12:11,599 --> 00:12:17,169
there is no such a thing such as a somatic mutation where for example,
00:12:17,179 --> 00:12:18,429
you're gonna have a behalf,
00:12:18,440 --> 00:12:18,659
00:12:18,669 --> 00:12:20,349
that indicates that the patient,
00:12:20,679 --> 00:12:20,919
00:12:20,929 --> 00:12:25,239
is likely to benefit or not from some treatment in immunology.
00:12:25,250 --> 00:12:26,750
This is far more complicated,
00:12:26,760 --> 00:12:28,830
complicated for the reason,
00:12:29,239 --> 00:12:31,020
starting with uh the fact that,
00:12:31,030 --> 00:12:31,179
00:12:31,190 --> 00:12:36,219
the response to this uh medication uh are multifactorial.
00:12:36,260 --> 00:12:37,820
And the fact that uh you know,
00:12:37,830 --> 00:12:39,380
the mutation that uh the,
00:12:39,390 --> 00:12:39,619
00:12:39,630 --> 00:12:45,190
the single nucleotide polymorphism in the GM line which uh uh you know,
00:12:45,200 --> 00:12:52,429
can potentially associate with uh with outcome uh uh uh uh a lo in advance,
00:12:52,440 --> 00:12:58,359
meaning that uh they're gonna have a weak association uh with a response to those medications.
00:12:58,369 --> 00:13:09,609
So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know,
00:13:09,619 --> 00:13:09,859
00:13:09,869 --> 00:13:10,380
00:13:10,390 --> 00:13:10,520
00:13:10,530 --> 00:13:13,219
the clinician uh you know,
00:13:13,419 --> 00:13:15,619
uh order the test and most importantly,
00:13:15,630 --> 00:13:15,840
00:13:15,849 --> 00:13:16,179
00:13:16,190 --> 00:13:17,739
the payer to pay for the test.
00:13:17,750 --> 00:13:20,469
So this field has been uh you know,
00:13:20,479 --> 00:13:20,679
00:13:20,690 --> 00:13:21,705
00:13:21,715 --> 00:13:21,994
00:13:22,005 --> 00:13:24,575
there are some tests that are being developed right now.
00:13:24,924 --> 00:13:39,034
But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient.
00:13:39,659 --> 00:13:41,200
I couldn't agree with you more.
00:13:41,210 --> 00:13:53,489
Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available,
00:13:53,500 --> 00:13:55,119
00:13:55,130 --> 00:13:59,760
it's sometimes difficult uh to get payers um to see the value.
00:13:59,770 --> 00:14:01,640
So I absolutely agree with you.
00:14:01,940 --> 00:14:03,679
Um The fact that you guys are,
00:14:03,690 --> 00:14:11,789
are uh investing in producing the data necessary says a lot about your laboratory.
00:14:11,979 --> 00:14:12,559
00:14:12,570 --> 00:14:15,380
and how committed you are to this testing and,
00:14:15,390 --> 00:14:17,320
and how you believe in the testing.
00:14:18,039 --> 00:14:23,640
So I just want to make sure that our audience recognizes that,
00:14:24,359 --> 00:14:24,619
00:14:24,630 --> 00:14:31,820
Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe.
00:14:32,190 --> 00:14:36,900
Um And maybe what the dose of the drug should be for the patient,
00:14:36,909 --> 00:14:40,219
but you have that whole suite of tests.
00:14:40,229 --> 00:14:47,380
Um the diagnostic test for the differential diagnosis all the way through remission.
00:14:48,030 --> 00:14:53,390
So can you elaborate you elaborated on it some in the previous question?
00:14:53,400 --> 00:15:01,229
But um can you tell us the difference between how you had to actually develop the test?
00:15:01,520 --> 00:15:02,530
00:15:02,539 --> 00:15:03,059
00:15:03,070 --> 00:15:10,659
purchase a test from another manufacturer with the biomarkers that you include in your testing.
00:15:10,669 --> 00:15:16,830
Can you elaborate on how much more difficult it is to to develop a test from scratch?
00:15:18,169 --> 00:15:18,320
00:15:18,330 --> 00:15:18,659
00:15:18,669 --> 00:15:18,809
00:15:18,820 --> 00:15:22,070
this is this is challenging for multiple and first of all,
00:15:22,080 --> 00:15:23,130
00:15:23,419 --> 00:15:27,450
you need to have a clinical data set available with specimen available.
00:15:27,460 --> 00:15:28,159
00:15:28,169 --> 00:15:28,780
00:15:28,859 --> 00:15:29,770
00:15:29,859 --> 00:15:30,890
00:15:31,200 --> 00:15:35,890
Uh So we are leveraging a pro meters a large bi bank of specimen.
00:15:36,299 --> 00:15:37,190
00:15:37,200 --> 00:15:39,719
Prometheus has been founded 25 years ago.
00:15:39,729 --> 00:15:40,599
00:15:40,760 --> 00:15:41,919
00:15:41,929 --> 00:15:54,849
we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will.
00:15:54,859 --> 00:16:07,559
And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity.
00:16:07,969 --> 00:16:11,469
Then we are entering validation phase where we are uh you know,
00:16:11,570 --> 00:16:14,789
using validation cohorts where we are again,
00:16:14,969 --> 00:16:22,630
combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker.
00:16:22,640 --> 00:16:23,190
00:16:23,500 --> 00:16:27,419
to come up with some Multivariate models that are uh again,
00:16:27,429 --> 00:16:39,250
bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer.
00:16:39,650 --> 00:16:41,190
00:16:41,200 --> 00:16:41,760
00:16:41,770 --> 00:16:45,320
the patient uh to the benefit of the patient and to,
00:16:45,330 --> 00:16:46,619
00:16:46,739 --> 00:16:47,429
00:16:48,340 --> 00:16:53,380
I think what you're describing really is the future of pharmacogenomics.
00:16:53,390 --> 00:16:54,599
00:16:54,609 --> 00:17:03,419
not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm.
00:17:03,559 --> 00:17:08,040
But using a PGX test in combination with,
00:17:08,050 --> 00:17:09,069
00:17:09,250 --> 00:17:11,160
00:17:11,170 --> 00:17:12,959
maybe other genetic tests.
00:17:13,290 --> 00:17:14,890
00:17:14,900 --> 00:17:25,869
I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to,
00:17:25,880 --> 00:17:26,910
00:17:27,239 --> 00:17:29,880
So I think you guys are absolutely,
00:17:29,890 --> 00:17:31,579
you're already in the future.
00:17:31,589 --> 00:17:32,849
00:17:32,859 --> 00:17:33,130
00:17:33,140 --> 00:17:39,689
you're already providing all these different uh tests um like you mentioned to,
00:17:39,699 --> 00:17:44,310
to facilitate from diagnosis to remission to remission.
00:17:44,660 --> 00:17:45,520
00:17:45,530 --> 00:17:45,829
00:17:46,349 --> 00:17:55,089
So um you've given us so much great information about uh the tests that that you guys offer.
00:17:55,329 --> 00:18:02,060
Can you explain to our audience um your newest test?
00:18:02,069 --> 00:18:03,859
00:18:04,150 --> 00:18:12,979
And um what role it will play in the paradigm from the diagnosis of IBD to remission?
00:18:14,050 --> 00:18:14,260
00:18:14,270 --> 00:18:14,760
00:18:14,770 --> 00:18:15,569
00:18:15,579 --> 00:18:18,069
we are doing things a little bit different than other.
00:18:18,079 --> 00:18:19,489
We do believe that uh you know,
00:18:19,500 --> 00:18:21,449
00:18:21,459 --> 00:18:24,189
Uh uh We can obviously construct some very,
00:18:24,199 --> 00:18:33,530
very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks,
00:18:33,540 --> 00:18:33,729
00:18:33,739 --> 00:18:34,790
00:18:34,800 --> 00:18:39,729
But we have taken on a different approach where with the responder test,
00:18:39,739 --> 00:18:40,329
00:18:40,339 --> 00:18:45,160
we are taking an approach which is very simple to address the first and foremost.
00:18:45,170 --> 00:18:53,020
Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics.
00:18:53,280 --> 00:19:03,250
Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately.
00:19:03,359 --> 00:19:06,349
And this is what we are doing with the responder test.
00:19:06,579 --> 00:19:09,010
We are addressing some uh uh you know,
00:19:09,020 --> 00:19:11,630
fundamental issues with those uh biologist,
00:19:11,640 --> 00:19:12,410
00:19:12,660 --> 00:19:15,170
uh the anti tumor necrosis factors.
00:19:15,180 --> 00:19:15,650
00:19:15,750 --> 00:19:19,199
such as uh Infliximab and Adalimumab,
00:19:19,209 --> 00:19:23,050
it is well known uh that uh uh those drugs,
00:19:23,060 --> 00:19:25,689
first of all are prone to immunization.
00:19:25,989 --> 00:19:36,949
Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells.
00:19:36,959 --> 00:19:42,209
If you will uh where you gonna have uh uh an immune uh uh response,
00:19:42,380 --> 00:19:56,979
uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects.
00:19:56,989 --> 00:19:57,150
00:19:57,160 --> 00:19:58,890
we are with the risk conductors,
00:19:58,900 --> 00:20:01,040
we are combining two things together.
00:20:01,189 --> 00:20:07,959
First of all is the genetic test itself which uh predicts the risk of immun immunization.
00:20:07,969 --> 00:20:18,010
The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the,
00:20:18,020 --> 00:20:19,130
00:20:19,140 --> 00:20:19,910
00:20:20,010 --> 00:20:20,750
00:20:20,760 --> 00:20:32,130
to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance,
00:20:32,140 --> 00:20:33,670
00:20:33,949 --> 00:20:36,209
Uh One of the key issue is the,
00:20:36,219 --> 00:20:36,770
00:20:36,780 --> 00:20:41,239
the monoclonal antibodies and uh such as Infliximab or Adalimumab.
00:20:41,329 --> 00:20:42,280
00:20:42,290 --> 00:20:45,890
a neon antibodies that those drugs are uh you know,
00:20:45,900 --> 00:20:49,010
cleared and consumed uh from the,
00:20:49,020 --> 00:20:50,949
from the central compartment if you will,
00:20:50,959 --> 00:20:54,520
since we are doing a little bit of uh uh pharmacokinetics here.
00:20:54,530 --> 00:20:56,020
00:20:56,030 --> 00:21:06,670
if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the,
00:21:06,680 --> 00:21:13,939
in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization.
00:21:13,949 --> 00:21:16,859
So I but this is a combination of both,
00:21:17,199 --> 00:21:19,359
these are the predictive factors of pharmacokinetic,
00:21:20,359 --> 00:21:38,209
which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient,
00:21:38,219 --> 00:21:38,300
00:21:38,310 --> 00:21:39,479
will clear the drug very,
00:21:39,489 --> 00:21:40,260
00:21:40,560 --> 00:21:41,670
00:21:41,680 --> 00:21:46,819
due to the inefficient uh recirculation of the drug itself with the new,
00:21:46,869 --> 00:21:46,930
00:21:46,939 --> 00:21:50,599
the the in the reticular on the system.
00:21:50,920 --> 00:21:51,619
00:21:51,630 --> 00:22:02,109
those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose,
00:22:02,380 --> 00:22:06,719
will not be responding to the drug uh adequately as and they,
00:22:06,729 --> 00:22:10,719
and they probably should in the first place if you are able to address uh you know,
00:22:10,729 --> 00:22:12,270
00:22:12,439 --> 00:22:14,079
So what we do with this test,
00:22:14,089 --> 00:22:21,640
we will be able to inform uh the clinic that the patient is at risk of achieving,
00:22:21,650 --> 00:22:30,829
of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately.
00:22:30,839 --> 00:22:38,650
So that the the the proper uh exposure is achieved uh during induction to again to,
00:22:38,660 --> 00:22:39,040
00:22:39,050 --> 00:22:39,380
00:22:39,390 --> 00:22:40,890
to achieve a better outcome.
00:22:41,040 --> 00:22:47,270
And I think the pharmacist will have a very important role to play here in terms of absolutely,
00:22:47,280 --> 00:22:51,239
that information is priceless in the management of these medications.
00:22:51,250 --> 00:22:54,930
So thanks for elaborating on that.
00:22:56,010 --> 00:22:59,040
And if I may add in our previous conversation,
00:22:59,050 --> 00:23:00,810
uh before the recording of podcast,
00:23:00,819 --> 00:23:08,869
we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test.
00:23:09,109 --> 00:23:14,109
But without stealing the Thunder from uh Prometheus market access and reimbursement team,
00:23:14,199 --> 00:23:22,619
can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem.
00:23:22,920 --> 00:23:27,349
Um the population health problem by building the evidence payers want,
00:23:27,359 --> 00:23:41,170
want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test.
00:23:42,160 --> 00:23:42,339
00:23:42,349 --> 00:23:43,180
00:23:43,189 --> 00:23:43,579
00:23:43,589 --> 00:23:46,619
I'm probably not the right person to answer that question.
00:23:46,630 --> 00:23:47,369
00:23:47,380 --> 00:23:52,400
very efficient market access group uh uh pro meters that does a splendid job.
00:23:52,410 --> 00:23:59,780
But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we,
00:23:59,790 --> 00:24:14,000
we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the,
00:24:14,010 --> 00:24:16,630
and the impact of our technology on the,
00:24:16,640 --> 00:24:18,119
00:24:18,430 --> 00:24:21,319
Uh We have uh uh already uh you know,
00:24:21,329 --> 00:24:25,160
commercialized uh two of those tests for which we have initiated,
00:24:25,170 --> 00:24:29,040
initiated the Power studies uh that uh uh you know,
00:24:29,050 --> 00:24:32,000
already provide uh you know,
00:24:32,104 --> 00:24:34,484
differentiated and the value to,
00:24:34,494 --> 00:24:35,915
to the payer where we are,
00:24:35,925 --> 00:24:36,025
00:24:36,035 --> 00:24:46,005
the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating,
00:24:46,145 --> 00:24:47,555
00:24:47,564 --> 00:24:48,574
00:24:48,584 --> 00:24:49,425
00:24:49,435 --> 00:24:49,915
00:24:49,925 --> 00:24:50,244
00:24:50,255 --> 00:24:53,594
the payer value you uh uh we can certainly follow up with,
00:24:53,604 --> 00:24:58,755
uh you can certainly follow up with our market access group uh uh as appropriate there.
00:24:58,765 --> 00:25:00,765
Uh They can fill you with more information.
00:25:01,349 --> 00:25:01,589
00:25:01,599 --> 00:25:02,520
that totally makes sense.
00:25:02,530 --> 00:25:03,310
That totally makes sense.
00:25:03,319 --> 00:25:10,890
But um we're excited that you're also farm d So how did you get to this role of outside the box path?
00:25:10,900 --> 00:25:11,550
00:25:11,640 --> 00:25:17,530
There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours,
00:25:17,540 --> 00:25:19,609
which is a Chief Scientific Officer.
00:25:19,619 --> 00:25:20,609
00:25:20,619 --> 00:25:23,920
So how would you um can you talk a little bit about that?
00:25:24,560 --> 00:25:24,780
00:25:24,790 --> 00:25:26,270
we are clinical laboratories.
00:25:26,280 --> 00:25:29,400
So in order to uh uh to be in my role,
00:25:29,410 --> 00:25:34,020
you need to have uh uh you need to have expertise in clinical laboratory science.
00:25:34,030 --> 00:25:36,140
So for the students is basically,
00:25:36,150 --> 00:25:36,300
00:25:36,310 --> 00:25:40,770
to do the family degree and then complete the family degree with uh a doctorate,
00:25:40,780 --> 00:25:40,930
00:25:40,939 --> 00:25:44,260
which is uh focus on clinical laboratory science.
00:25:44,270 --> 00:25:46,079
So you can achieve uh uh you know,
00:25:46,089 --> 00:25:47,640
the all the elements you need to be,
00:25:47,650 --> 00:25:48,219
00:25:48,229 --> 00:25:53,189
board certified uh as uh as as medical laboratory director.
00:25:53,199 --> 00:25:55,160
00:25:55,170 --> 00:25:55,589
00:25:55,599 --> 00:25:56,030
00:25:56,040 --> 00:25:56,400
00:25:56,410 --> 00:25:57,209
00:25:57,219 --> 00:25:59,160
a great opportunity I think for pharmacies,
00:25:59,170 --> 00:26:10,800
there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease,
00:26:10,810 --> 00:26:15,229
the effectiveness of the therapy and um and uh you know,
00:26:15,239 --> 00:26:16,060
00:26:16,069 --> 00:26:20,969
the side effect and the toxicity from uh from those uh those medication.
00:26:24,650 --> 00:26:24,959
00:26:24,969 --> 00:26:32,119
the I know our audience is going to have uh additional questions for you.
00:26:32,130 --> 00:26:32,540
00:26:32,989 --> 00:26:35,609
you've provided them with so much great information,
00:26:35,619 --> 00:26:44,959
but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and,
00:26:44,969 --> 00:26:46,729
and even your career path.
00:26:47,050 --> 00:26:47,530
00:26:47,540 --> 00:26:49,300
if you wouldn't mind telling us,
00:26:49,310 --> 00:26:51,359
um because we have to wrap up,
00:26:51,369 --> 00:26:52,670
00:26:53,150 --> 00:26:55,810
this episode of the podcast,
00:26:55,819 --> 00:27:00,250
uh could you tell us how our audience members might be able to contact you directly.
00:27:01,260 --> 00:27:01,449
00:27:01,459 --> 00:27:07,079
I can be contacted on my uh on my email at TT W at como slab dot com.
00:27:07,949 --> 00:27:08,810
00:27:09,069 --> 00:27:09,300
00:27:09,310 --> 00:27:14,290
thank you again so much uh for joining us on this episode.
00:27:14,300 --> 00:27:15,290
00:27:15,300 --> 00:27:29,530
really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite.
00:27:29,709 --> 00:27:35,670
We really hope that our a our audience will um listen in and learn this information.
00:27:36,280 --> 00:27:37,869
00:27:37,880 --> 00:27:39,439
00:27:39,449 --> 00:27:42,619
We really hope that you've learned from this episode.
00:27:43,130 --> 00:27:46,339
Uh We do a whole lot of PG Xing here on this podcast.
00:27:46,349 --> 00:27:48,380
We talk about PGX Science,
00:27:48,390 --> 00:27:52,030
clinical application and the business of PGX.
00:27:52,260 --> 00:27:54,880
So we'd love to hear about from you.
00:27:55,099 --> 00:27:56,479
00:27:56,489 --> 00:27:58,439
Um What can we teach you?
00:27:58,449 --> 00:28:00,920
What more can we teach you through our podcast?
00:28:00,930 --> 00:28:12,349
So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast.
00:28:12,520 --> 00:28:15,369
Leave us a review on Apple podcast or Spotify.
00:28:15,459 --> 00:28:18,130
And you can also visit us on PGX four,
00:28:18,140 --> 00:28:22,989
the number four Rx dot com to listen to all our other episodes.
00:28:23,000 --> 00:28:23,079
00:28:23,089 --> 00:28:23,790
00:28:24,199 --> 00:28:28,750
Thanks for your interest in PGX and for spending some time with us.
00:28:28,760 --> 00:28:35,670
Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes.
00:28:35,680 --> 00:28:39,390
Please visit PGX four Rx dot com.
00:28:39,569 --> 00:28:43,380
That's PGX four Rx dot com.
